You just read:

Mylan and Biocon to Present New Data at the American Society of Clinical Oncology (ASCO) Annual Meeting Reinforcing the Efficacy, Safety and Immunogenicity of Ogivri™, the first biosimilar for Herceptin® approved by FDA

News provided by

Mylan N.V.

Jun 01, 2018, 05:18 ET